SciBase, a Swedish firm, won FDA approval to introduce its Nevisense system to help dermatologists assess suspect cutaneous Lesions that may be mela**ma tumors. Unlike many tech**logies that have been attempted to characterize cancerous lesions, this one uses Electrical impedanceآ*rather than optical methods.
The system delivers electric current at different frequencies through the lesion using a pen-like device. Mela**ma tumor cells transmit electricity somewhat differently from **rmal healthy cells, and the effect of this can be detected using Electrical Impedance spectroscopy. Reference measurements taken in the past allow the system to compare with those and point to suspect mela**ma during the exam.
The physician simply moistens the skin over the lesion, wipes off, and measures by placing the pen tip against the lesion. The table-top touchscreen display then provides a spectrogram of the readings and how out of **rmal range they are.
Having this information dermatologists may then be able to form a better idea of whether to move toward Biopsy of the suspect lesion.
Here’s an info video from SciBase about Nevisense:
07-06-2017, 06:15 AM
Nevisense Electrical Impedance Spectroscopy to Test Lesions Before Biopsy for Mela**m
العرض العادي
